REQUEST A DEMO
Total
USD $0.00
Search more companies

Janssen-Cilag Kft. (Hungary)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers | Pharmaceutical and Medicine Manufacturing
Secondary Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Full name: Janssen-Cilag Gyogyszerkereskedelmi Marketing Szolgaltato Kft. Profile Updated: September 11, 2020
Buy our report for this company USD 29.95 Most recent financial data: 2019 Available in: English & Hungarian Download a sample report

We are actively developing treatments for patients in five important therapeutic areas of healthcare: Cardiovascular & Metabolic diseases, Immunology, Infectious diseases & vaccines, Neuroscience and Oncology. Through extensive medical research our solutions may be able to alleviate, contain or cure some of the world’s most serious conditions and diseases.

Headquarters
Nagyenyed utca 8-14.
Budapest; Budapest; Postal Code: 1123

Contact Details: Purchase the Janssen-Cilag Kft. report to view the information.

Website: http://www.janssen-cilag.hu

Basic Information
Total Employees:
Purchase the Janssen-Cilag Kft. report to view the information.
Registered Capital:
Purchase the Janssen-Cilag Kft. report to view the information.
Financial Auditors:
Purchase the Janssen-Cilag Kft. report to view the information.
Incorporation Date:
December 18, 2003
Key Executives
Purchase this report to view the information.
Managing Director
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Actelion Pharmaceuticals Hungaria Kft.
Company Performance
Financial values in the chart are available after Janssen-Cilag Kft. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
18.44%
Total operating revenue
18.17%
Operating profit (EBIT)
-38.79%
EBITDA
-34.62%
Net Profit (Loss) for the Period
N/A
Total assets
24.07%
Total equity
-2.28%
Operating Profit Margin (ROS)
-1.56%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Quick Ratio
-0.17%
Cash Ratio
-0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?